Cardiff Oncology financials
$1.17−2.50%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $104.0K | $41.0K | $243.0K | $120.0K | $121.0K | $109.0K | $151.0K | $165.0K | $163.0K | $205.0K | $156.0K | $141.0K |
| Gross profit | $104.0K | $41.0K | $243.0K | $120.0K | $121.0K | $109.0K | $151.0K | $165.0K | $163.0K | $205.0K | $156.0K | $141.0K |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$9.6M | -$12.8M | -$7.8M | -$12.0M | -$14.8M | -$14.4M | -$12.6M | -$12.6M | -$12.5M | -$10.9M | -$10.3M | -$10.8M |
| Net income | -$9.2M | -$12.4M | -$7.2M | -$11.3M | -$13.9M | -$13.4M | -$11.8M | -$11.9M | -$11.8M | -$10.0M | -$9.3M | -$9.7M |
| Net margin | −8882.7% | −30124.4% | −2972.4% | −9386.7% | −11528.1% | −12330.3% | −7809.9% | −7188.5% | −7229.4% | −4886.3% | −5989.1% | −6905.7% |
| Diluted EPS | $-0.14 | $-0.18 | $-0.11 | $-0.17 | $-0.21 | $-0.20 | $-0.22 | $-0.25 | $-0.26 | $-0.22 | $-0.21 | $-0.22 |
| EBITDA | -$9.5M | -$12.8M | -$7.7M | -$11.9M | -$14.7M | -$14.3M | -$12.5M | -$12.5M | -$12.4M | -$10.8M | -$10.2M | -$10.7M |
| Operating cash flow | -$11.8M | -$12.3M | -$6.0M | -$10.8M | -$8.3M | -$12.8M | -$10.3M | -$10.5M | -$9.2M | -$7.7M | -$7.1M | -$8.0M |
| Free cash flow | -$11.8M | -$12.3M | -$6.0M | -$10.9M | -$8.4M | -$12.8M | -$10.3M | -$10.5M | -$9.2M | -$7.8M | -$7.1M | -$8.3M |
| Diluted shares | 68.4M | 68.4M | 67.4M | 66.9M | 66.5M | 66.5M | 54.2M | 46.9M | 44.8M | 44.7M | 44.7M | 44.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $9.2M | $8.5M | $17.5M | $10.1M | $10.8M | $24.1M |
| Short-term investments | $25.3M | $37.5M | $40.8M | $50.5M | $60.2M | $55.8M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $37.3M | $49.2M | $61.9M | $63.8M | $75.7M | $84.8M |
| Total liabilities | $10.8M | $14.5M | $16.5M | $15.0M | $17.1M | $13.9M |
| Shareholders' equity | $26.5M | $34.7M | $45.4M | $48.8M | $58.6M | $70.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology